Novavax Sees Surge in Share Value Following Partnership Agreement with Sanofi

Friday, 10 May 2024, 09:00
Novavax's stock experienced a significant increase due to a new $1.4 billion deal with Sanofi. The collaboration aims to market Novavax's current COVID-19 vaccine and co-create a combined vaccine for COVID-19 and Influenza. This strategic partnership is expected to propel both companies forward in the competitive pharmaceutical landscape.
https://store.livarava.com/fa886ab3-0eab-11ef-a6c2-63e1980711b2.jpg
Novavax Sees Surge in Share Value Following Partnership Agreement with Sanofi

Novavax Shares Surge with Sanofi Deal

The recent agreement between Novavax and Sanofi has led to a considerable rise in Novavax's stock value. This collaboration entails the commercialization of Novavax's already existing COVID-19 vaccine, along with mutual efforts to develop a new combined vaccine that targets both COVID-19 and Influenza.

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe